Please assess the completion status of the following clinical trial:

Trial Title: Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. At least 18 years of age.~2. NDD-CKD subjects with an estimated glomerular filtration rate (eGFR) ≤60 mL/min/1.73 m2 using modification of diet in renal disease 4 (MDRD-4) calculation.~3. NDD-CKD subjects with an eGFR loss ≤12 mL/min/1.73 m2/year and a predicted eGFR of ≥15 mL/min/1.73 m2 in 12 months.~4. Any single Hb between 9 and 11 g/dL within 4 weeks of randomisation. A value taken as part of routine medical care was used.~5. Any single serum ferritin \<100 mcg/L or \<200 mcg/L with TSAT \<20% within 4 weeks of randomisation. Measurements taken as part of routine medical care were used.~6. ESA naïve; no exposure to ESA in last 4 months prior to randomisation.~7. Females of childbearing potential must have had a negative pregnancy test, using any medically acceptable assessment, prior to randomisation.~8. Before any study specific procedure, the appropriate written informed consent must have been obtained.~Exclusion Criteria:~1. History of acquired iron overload.~2. Known hypersensitivity reaction to any component of ferrous sulphate or FCM. Subjects with hypersensitivity to other forms of iron were permitted to participate.~3. Documented history of discontinuing oral iron products due to significant gastrointestinal (GI) distress.~4. Screening TSAT \>40%.~5. Known active infection, C-reactive protein \>20 mg/L, clinically significant overt bleeding, active malignancy (i.e., clinical evidence of current malignancy or not in stable remission for at least 5 years since completion of last treatment with exception of basal cell or squamous cell carcinoma of the skin, and cervical intraepithelial neoplasia).~6. History of chronic alcohol abuse (alcohol consumption \>40 g/day).~7. Chronic liver disease and/or screening alanine transaminase or aspartate transaminase above 3 times the upper limit of the normal range.~8. Active human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome or active hepatitis B or C virus infection.~9. Anaemia due to reasons other than iron deficiency (e.g., haemoglobinopathy). Subjects with treated Vitamin B12 or folic acid deficiency were permitted.~10. IV iron and/or blood transfusion in previous 30 days prior to screening (or during the screening period).~11. Oral iron therapy at doses \>100 mg/day dosing must have been discontinued at least 1 week prior to randomisation. If subject had received this therapy for \>3 months (at doses \>100 mg/day) then subject was not eligible. Ongoing use of multivitamins containing iron was permitted.~12. Immunosuppressive therapy that may have led to anaemia (e.g., cyclophosphamide, azathioprine, or mycophenolate mofetil). Steroid therapy was permitted.~13. Currently requiring renal dialysis.~14. Anticipated dialysis or transplant during the study.~15. Anticipated need for surgery that may have resulted in significant bleeding (\>100 mL).~16. Currently suffering from chronic heart failure New York Heart Association Class IV.~17. Poorly controlled hypertension (\>160 mmHg systolic pressure or \>100 mmHg diastolic pressure).~18. Acute coronary syndrome or stroke within the 3 months prior to screening.~19. Currently suffering from concomitant, severe psychiatric disorders or other conditions which, in the opinion of the Investigator, would have made participation unacceptable.~20. Subject was not using adequate contraceptive precautions.~21. Subject of childbearing potential was evidently pregnant (e.g., positive human chorionic gonadotropin test) or was breast feeding.~22. Body weight \<35 kg.~23. Subject currently was enrolled in or had not yet completed at least 30 days since ending other investigational device or drug studies, or subject was receiving other investigational agent(s).~24. Subject would not be available for follow-up assessment.~25. Subject had any kind of disorder that compromised the ability of the subject to give written informed consent and/or to comply with study procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FCM (high ferritin target) (Type: EXPERIMENTAL): Ferric carboxymaltose (FCM) (Ferinject / Injectafer) targeting ferritin level of 400 - 600 mcg/L
- FCM (low ferritin target) (Type: EXPERIMENTAL): Ferric carboxymaltose (FCM) (Ferinject / Injectafer) targeting ferritin level of 100 - 200 mcg/L
- Oral Iron (Type: ACTIVE_COMPARATOR): Ferrous sulphate 100 mg iron twice daily, continuous

Based on this trial design, predict the completion outcome and termination type (if applicable).